Review Article

Evidence and Potential Mechanisms of Traditional Chinese Medicine for the Adjuvant Treatment of Coronary Heart Disease in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis with Trial Sequential Analysis

Yu Wei 1,2, Qi-You Ding 1,2, Chak Yeung 1, Yi-shan Huang 1, Bo-xun Zhang 1, Li-li Zhang 1, Run-Yu Miao 1,2, Sha Di 3, Lin-Hua Zhao 1, and Xiao-Lin Tong 1

1Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
2Graduate College, Beijing University of Traditional Chinese Medicine, Beijing 100029, China
3Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China

Correspondence should be addressed to Sha Di; 13051153725@163.com, Lin-Hua Zhao; melonzhao@163.com, and Xiao-Lin Tong; tongxiaolin@vip.163.com

Received 8 September 2021; Revised 9 March 2022; Accepted 27 July 2022; Published 31 August 2022

Copyright © 2022 Yu Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Traditional Chinese medicine (TCM) has long been used to treat diabetes mellitus and angina. It has also gained widespread clinical applications in China as a common adjuvant treatment. Although there is high-quality evidence that TCM is effective in regulating glucose and lipid metabolism, the cardiovascular protective effect of TCM in the treatment of diabetes mellitus has not been fully elucidated, especially in patients with both diabetes mellitus and coronary heart disease (CHD). We systematically assessed the efficacy and safety of TCM for the adjuvant treatment of patients with CHD and diabetes mellitus and examined the pharmacological effects and potential mechanisms of TCM medication/herbs on diabetes mellitus with CHD. We found that TCM could improve the control effect of conventional treatment on cardiac function, hemorheology, blood glucose, blood lipid, and inflammation, thus reducing the frequency of angina and the incidence of cardiovascular events and all-cause mortality. These findings indicate that TCM may be used as a complementary approach for patients with diabetes mellitus and CHD. Nevertheless, more rigorously designed randomized controlled trials and long-term evaluations are needed to support these findings.

1. Introduction

The global population of patients with diabetes mellitus (DM) is approximately 463 million, which is expected to rise to 700 million by 2040 [1]. As an independent risk factor for coronary heart disease (CHD), DM is considered as “coronary heart disease equivalent” [2], which is associated with increased CHD morbidity and mortality [3]. In patients with DM, the risk of mortality due to CHD is twice that of those who do not have DM [4]. Clinical outcomes and complications following coronary interventions are also worse in such high-risk patients [5]. Several medical resources are spent on DM every year. The total global health expenditure due to DM was estimated to be $673 billion in 2015 [6], with cardiovascular diseases attributable to diabetes accounting for the highest proportion (47.9%) of overall costs [7]. However, the need to control cardiovascular diseases is still unmet. At present, the treatment for DM, especially in those with a high atherosclerotic cardiovascular disease risk, mainly focuses on comprehensively controlling multiple risk factors [8]. However, the complexity of multidrug regimens may induce the chance of nonadherence among patients, while long-term use of high-intensity antiplatelet drugs and lipid-lowering statins may increase the incidence of side effects, such as bleeding, muscle complaints, increased liver or muscle enzymes, or various neurological symptoms [9].
Therefore, clinicians have begun considering traditional Chinese medicine (TCM) as an adjuvant or alternative treatment for DM.

TCM has been widely used to treat diabetes and angina for 1000 years. The holistic and multitarget approaches of TCM have unique advantages in controlling complex diseases, such as DM [10]. In recent years, large-scale clinical trials have demonstrated that TCM effectively reduces hyperglycemia [11–13] and improves vascular inflammation, lowers lipids, and improves cardiac function [14, 15]. A large-sample prospective cohort study also showed that TCM alone is as efficacious as Western medicines in preventing diabetes from being complicated with coronary artery disease [16]. Moreover, patients who used more types of TCM tended to use much less Western medicine recommended by current guidelines [17]. At the same time, some therapeutic mechanisms underlying TCM’s potency have been uncovered with the application of modern science and technology.

A number of clinical trials in China have shown that TCM is effective in treating DM or CHD. However, because of the insufficient sample size, short experimental period, and lack of empirical validity of efficacy evaluation in many studies, the results have been questioned and rejected. To date, there are very few systemic analyses that have focused on the comprehensive regulation effect of TCM adjuvant treatment on both DM and CHD. Considering the aforementioned limitations, we selected more credible studies for a systematic review and meta-analysis to comprehensively evaluate the clinical efficacy and safety of TCM for patients with CHD and DM.

2. Materials and Methods

We conducted and reported this systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [18].

2.1. Search Strategy. The first three authors independently searched for papers published from January 2005 to May 2021 on the following databases: the China National Knowledge Internet, Wanfang, VIP databases, the China Biology Medicine, Web of Science, Pubmed, Medline; Embase, International Pharmaceutical Abstracts, and the Cochrane Library. Search terms were as follows: (“coronary heart disease” or “cardiovascular disease” or “angina” or “myocardial ischemia” or “myocardial infarction” or “acute coronary syndrome” or “coronary atherosclerosis”) and (“diabetes” or “diabetes mellitus” or “Xiaoke syndrome”) and (“randomized controlled trial” or “controlled clinical trial” or “random” or “randomly” or “randomized” or “control” or “RCT”) and (“TCM” or “traditional Chinese medicine” or “Chinese medicinal herb” or “Chinese herbal medicine” or “decocition” or “formula” or “prescription” or “Chinese patent medicine” or “Chinese patent drug” or “Chinese herbal compound prescription”). The PRISMA flow chart for the study is presented in Figure 1.
2.2. Inclusion Criteria and Study Selection. Clinical studies were included if they satisfied the following criteria: (1) study participants had a definite diagnosis of both DM and CHD and were randomly assigned to receive TCM, contemporary medication, or placebo; (2) the sample size was ≥100; (3) the duration in each study group was ≥8 weeks. Clinical studies with the following features were excluded: (1) non-randomized trials; (2) the participants had no definite diagnosis; and (3) only symptomatic changes of participants were reported, without objective laboratory measurements or physical examination. As many randomized controlled trials (RCTs) on TCM have been published in Chinese, published reports in both English and Chinese were included. The first two authors (Ding and Wei) independently reviewed all titles and abstracts. If the information was insufficient, the full text was retrieved for further judgment. If the two authors failed to reach a consensus, the senior author (Zhao) made the final judgment.

2.3. Quality Assessment. The quality of the included studies was assessed independently by the first two authors (Wei and Ding) as defined by the Cochrane’s risk of bias tool [19]. The risk of bias was assigned as low, unclear, or high for the following items: random sequence generation, Table 1: Summary of included studies.

| Study | Patient group | Control (M/W) | Treatment | Duration | Outcomes |
|-------|---------------|---------------|------------|----------|----------|
| Chen 2019 | T2DM&CHD 128 | 64 (29/35) | CT | Yanshi Yixin decoction+CT | 3 m | BG, BL, SAA, MMP-9, TBIL |
| Cheng 2019 | T2DM&CHD 118 | 60 | 58 | Supplemented Yuuye decoction+CT | 3 m | BG, BL, IM, SOD, MDA, GSH-Px, 8-ios-PGF2α |
| Feng 2020 | T2DM&CHD 130 | 65 (33/32) | 65 (35/30) | CT | Shexiang Baoxin Pill+CT | 3 m | BL |
| Gao 2018 | T2DM&CHD 100 | 50 (27/23) | 50 (24/26) | CT | Shengmai powder+CT | 2 m | BG, BL, PGF-21, Ghrelin |
| Li 2008 | DM&CHD 100 | 50 (33/17) | 50 (32/18) | CT | Jiangtang Shengmaii decoction+CT | 2 m | BG, BL, HI |
| Li 2021 | T2DM&CHD 286 | 143 (75/68) | 143 (76/67) | CT | Tongxinluo capsule+CT | 3 m | CF, BL, BG |
| Liu 2008 | T2DM&CHD 260 | 130 (95/35) | 130 (89/41) | CT | Xinshu pill+CT | 2 m | BG, IM, DD, LFTs, KFTs |
| Liu 2019 | T2DM&CHD 108 | 54 (29/25) | 54 (28/26) | CT | Shexiang Yangxin powder+CT | 3 m | BG, BL, HI |
| Ni 2010 | T2DM&CHD 173 | 45 (21/24) | 128 (55/73) | CT | Qiizi Jiangtang capsule+CT | 2 m | BG, dynamic ECG |
| Ning 2017 | T2DM&CHD 150 | 75 (34/41) | 75 (35/40) | CT | Yindan Xinnaoartment soft capsule+CT | 3 m | HI, angina frequency |
| Pan 2019 | T2DM&SAP 120 | 60 (29/31) | 60 (28/32) | CT | Yiqi Yangxin Huoxue decoction_CT | 3 m | BG, BL, CRP, Hcy, UMA |
| Qian 2017 | DM&ACS 294 | 147 (97/50) | 147 (102/45) | CT | Xinyue capsule+CT | 6 m | CE, BG, NT-proBNP, CK-MB |
| Qian 2018 | T2DM&CHD 150 | 75 (43/32) | 75 (45/30) | CT | Tongguan Huoxue decoction+Naoxintong capsule+CT | 3 m | BG, BL, HMGMB1, Omentin-1 |
| Ren 2020 | T2DM&CHD 320 | 160 (85/75) | 160 (78/82) | CT | Tongguan Huoxue decoction+Naoxintong capsule+CT | 3 m | CF, BG |
| Shi 2020 | T2DM&CHD 120 | 60 (16/44) | 60 (18/42) | CT | Yindan Xinnaoartment soft capsule+CT | 3 m | Angina frequency, BL |
| Tao 2017 | T2DM&CHD 118 | 55 (33/22) | 63 (43/20) | CT | Hedan pill+CT | 6 m | BL, IM, SOD, MDA, NO |
| Zhang 2015 | T2DM&CHD 102 | 51 (30/21) | 51 (28/23) | CT | Shuxin Huoxue decoction+CT | 2 m | BL, IM, HI |
| Zhang 2019 | T2DM&SAP 179 | 81 (43/38) | 98 (49/49) | CT | Yiqi Yangxin decoction+CT | 3 m | CE, BG, BL, HI, IM |
| Zhang 2020 | DM&CHD 134 | 67 (36/31) | 67 (34/33) | CT | Xuezhikang+CT | BG, BL, HI, IM, CF |
| Zhao 2007 | T2DM&CHD 591 | 285 (198/87) | 306 (226/80) | Placebo+CT | Xuezhikang+CT | 4 y | ACM, CE, BL |

ACS: acute coronary syndrome; SAP: stable angina pectoris; CT: conventional treatment; ACM: all-cause mortality; CE: cardiovascular events; CF: cardiac function; HI: hemorrhheologic indices; IM: inflammatory marks; BG: blood glucose; BL: blood lipid.
| Study         | Prescription                  | Medicine                                                                 | Article |
|--------------|-------------------------------|---------------------------------------------------------------------------|---------|
| Chen 2019    | Yan’s yixin prescription     | Dasheng (Radix Codonopsis), Huangqin (Radix Astragali seu Hedysari), Juemingzi (Semen Cassiae), Gegen (Radix Puerariae), Shichangpu (Rhizoma Acori Tatarinowii), Jiangxiang (Lignum Dalbergiae Odoriferae), Danshen (Radix Salviae Miltiorrhiza), Chuanxiong (Rhizoma Ligustici Chuanxiong), Chishao (Radix Paeoniae Rubra), Shanzha (Fructus Crataegi), Fabanxia (Rhizoma Pinelliae Preparatum), Zhiqiao (Fructus Aurantii) | [22]    |
| Cheng 2019   | Modified Yuyetang            | Shanyao (Rhizoma Dioscoreae), Taizishen (Radix Pseudostellariae), Huangqi (Radix Astragali seu Hedysari), Zhimu (Rhizoma Anemarrhena), Gegen (Radix Puerariae), Wuweizi (Fructus Schisandraceae Chinensis), Tianhuafen (Radix Trichosanthis), Jinejin (Endothelium Corneum Gigeriae Galli), Danshen (Radix Salviae Miltiorrhiza), Sanqi (Radix Notoginseng), Chuanxiong (Rhizoma Ligustici Chuanxiong), Honggu (fermentum rubrum), Fabanxia (Rhizoma Pinelliae Preparatum), Chenpi (Pericarpium Citri Reticulatae), Gancao (Radix Glycyrrhiza) | [23]    |
| Feng 2020    | Shexiang Baoxin Pill         | Shexiang (Moschus), Renshen (Radix Ginseng), Niuhuang (Calculus Bovis), Rougui (Cortex Cinnamomi), Anxixiang (Benzoinum), Chansu (Venenum Bufonis), Bingpian (Borneolum Syntheticum) | [46]    |
| Gao 2018     | Shengmai powder              | Gancao (Radix Glycyrrhiza), Wuweizi (Fructus Schisandraceae Chinensis), Huangqin (Radix Astragali seu Hedysari), Renshen (Radix Ginseng), Chuanxiong (Rhizoma Ligustici Chuanxiong), Maidong (Radix Ophiopogonis), Gegen (Radix Salviae Miltiorrhiza), Sanqi (Radix Notoginseng) | [24]    |
| Li 2008      | Shengmai powder              | Renshen (Radix Ginseng), Huangqin (Radix Astragali seu Hedysari), Shanyao (Rhizoma Dioscoreae), Cangzhu (Rhizoma Atractylodis), Xuanshen (Radix Scrophulariae), Danggui (Radix Angelicae Sinensis), Shudi (Radix Rehmanniae Preparata), Maidong (Radix Ophiopogonis), Wuweizi (Fructus Schisandraceae Chinensis), Danshen (Radix Salviae Miltiorrhiza), Chuanxiong (Rhizoma Ligustici Chuanxiong), Chishao (Radix Paeoniae Rubra), Yanhusuo (Rhizoma Corydalis), Gancao (Radix Glycyrrhiza) | [25]    |
| Liu 2008     | Xinshu pills                 | Huangqi (Radix Astragali seu Hedysari), Danshen (Radix Salviae Miltiorrhiza), Gegen (Radix Puerariae), Danggui (Radix Codonopsis), Shuizhi (Hirudo), Jiezi (Semen Sinapis Albae), Huangjing (Rhizoma Polygonati), Maidong (Radix Ophiopogonis), Wuweizi (Fructus Schisandraceae Chinensis) | [26]    |
| Liu 2019     | Shexiangyangxin powder       | Danshen (Radix Salviae Miltiorrhiza), Xiebai (Bulbus Allii Macrostemonis), Maidong (Radix Ophiopogonis), Chishao (Radix Paeoniae Rubra), Renshen (Radix Ginseng), Guizhizhui (Guangmu), Jiezi (Semen Sinapis Albae), Huangjing (Rhizoma Polygonati), Maidong (Radix Ophiopogonis), Wuweizi (Fructus Schisandraceae Chinensis) | [27]    |
| Li 2019      | Qizhi jiangtang capsule      | Qizhi (Folium Ginkgo), Danshen (Radix Salviae Miltiorrhiza), Xixin (Herba Asari), Jiaoqian (Gynostemma pentaphylla), Shanzha (Fructus Crataegi), Sanqi (Radix Notoginseng), Aiyi (Folium Artemisiae Argyi) | [48]    |
| Ning 2017    | Yindan Xinnao tong soft capsule | Yinxingye (Folium Ginkgo), Danshen (Radix Salviae Miltiorrhiza), Xixin (Herba Asari), Jiaoqian (Gynostemma pentaphylla), Shanzha (Fructus Crataegi), Sanqi (Radix Notoginseng), Aiyi (Folium Artemisiae Argyi) | [29]    |
| Pan 2019     | Yiqi yangxin huoxue recipe  | Taizishen (Radix Pseudostellariae), Huangqi (Radix Astragali seu Hedysari), Danggui (Radix Angelicae Sinensis), Shudi (Radix Rehmanniae Preparata), Danshen (Radix Salviae Miltiorrhiza), Guizhi (Ramulus Cinnamomi), Wuweizi (Fructus Schisandraceae Chinensis), Shanqi (Radix Notoginseng), Aiye (Folium Artemisiae Argyi) | [35]    |
| Qian 2017    | Moods capsule                | Panxun quinquefolium saponin, Shudi (Radix Rehmanniae Preparata), Xiyangshen (Radix Panacis Quinquefolii), Huangjing (Rhizoma Polygonati), Sanqi (Radix Notoginseng), Aiye (Folium Artemisiae Argyi) | [32]    |
| Qian 2018    | Tongguan huoxue decoction   | Huangqin (Radix Salviae Miltiorrhiza), Maidong (Radix Ophiopogonis), Gualou (Fructus Trichosanthis), Honghua (Flos Carthami), Chuanxiong (Rhizoma Ligustici Chuanxiong), Dilong (Lumbricus), Chaihu (Radix Bupleuri), Gancao (Radix Glycyrrhiza) | [21]    |
| Ren 2020     | Tongxinluo, Jinlida          | Renshen (Radix Ginseng), Shuizhi (Hirudo), Quanxi (Scorpio), Chishao (Radix Paeoniae Rubra), Chantui (Periostracum Cicadae), Tubiechong (Eupolyphaga Seu Steleophaga), Wugong (Scolopendra), Tanxiang (Lignum Santali Albi), Chengpi (Pericarpium Citri Reticulatae), Yanhusuo (Rhizoma Corydalis), Gegen (Radix Glycyrrhiza) | [47, 49] |
### Table 2: Continued.

| Study      | Prescription                        | Medicine                                                                 | Article |
|------------|-------------------------------------|--------------------------------------------------------------------------|---------|
| Shi 2020   | Yindan Xinaotong soft capsule       | Atractylodis), Baizhu (Rhizoma Atractylodis Macrocephalae), Gegen (Radix Puerariae), Yuzhu (Rhizoma Polygonati Odorati), Fuling (Poria) | [39]    |
| Tao 2017   | Hedan tablets                       | Yinxingye (Folium Ginkgo), Danshen (Radix Salviae Miltiorrhizae), Xixin (Herba Asari), Jiaogulan (Gynostemma pentaphylla), Shanzha (Fructus Crataegi),Sanqi (Radix Notoginseng), Aiye (Folium Artemisiae Argyi) | [30]    |
| Zhang 2015 | Shuxin huoxue decoction             | Heye (Folium Nelumbinis), Danshen (Radix Salviae Miltiorrhizae), Shanzha (Fructus Crataegi), Fanxieye (Folium Sennae), Buguzhi (Fructus Psoraleae) | [33]    |
| Zhang 2017 | Shexiang Baoxin Pill                | Huangqi (Radix Astragali seu Hedysari), Maidong (Radix Ophiopogonis), Danshen (Radix Salviae Miltiorrhizae), Huangjing (Rhizoma Polygonati), Shuizhi (Hirudo), Jiezhi (Semen Sinapis Albae), Dasheng (Radix Codonopsis), Wuweizi (Fructus Schisandraceae Chinensis) | [34]    |
| Zhang 2019 | Yiqi yangyin basic prescription     | Danshen (Radix Salviae Miltiorrhizae), Xiebai (Bulbus Allii Macrostemonis), Maidong (Radix Ophiopogonis), Chishao (Radix Paeoniae Rubra), Renshen (Radix Ginseng), Guizhi (Ramulus Cinnamomi), Wuweizi (Fructus Schisandraceae Chinensis), Shuizhi (Hirudo), Jiezi (Semen Sinapis Albae), Dasheng (Radix Codonopsis), Wuweizi (Fructus Schisandraceae Chinensis) | [31]    |
| Zhang 2020, Zhao 2007 | Xuezhikang | Honggu (fermentum rubrum) | [41, 36] |

![Figure 2: Evaluation of the risk of bias for each included study using the Cochrane Risk of Bias Tool.](image)

2.4. Data Extraction and Analysis. Data extraction was individually performed by the same authors (Wei and Ding) in an unblended standardized manner. In case of discrepancies,
Study | Intervention | Experiment Events | Total | Control Events | Total | RR (95% CI) | %Weight
--- | --- | --- | --- | --- | --- | --- | ---
Qian 2017 | Moods capsule | 0 | 147 | 6 | 147 | 0.077 (0.004, 1.353) | 12.24
Zhang 2019 | Yiqi yangyin basic prescription | 0 | 98 | 0 | 81 | 0.559 (0.357, 0.876) | 87.76
Zhao 2007 | Xuezhikang | 27 | 306 | 45 | 285 | (Excluded) | 0
Overall (I-squared = 46.6%, p = 0.171) | | | | | | 0.5 (0.322, 0.775) | 0

**Figure 3:** Forest plot of relative risk of all-cause mortality. RR: relative risk; CI: confidence interval.

Required information size is a two-sided graph

**Figure 4:** Trial sequential analysis of mortality.

Study | Intervention | Experiment Events | Total | Control Events | Total | RR (95% CI) | %Weight
--- | --- | --- | --- | --- | --- | --- | ---
Qian 2017 | | 13 | 147 | 32 | 147 | 0.406 (0.222, 0.742) | 31.99
Zhao 2007 | | 28 | 306 | 53 | 285 | 0.492 (0.321, 0.755) | 54.87
Zhang 2019 | | 8 | 98 | 12 | 81 | 0.551 (0.237, 1.283) | 13.14
Overall (I-squared = 0.0%, p = 0.818) | | | | | | 0.472 (0.342, 0.652) | 100

**Figure 5:** Forest plot of relative risk of incidence of cardiovascular events. RR: relative risk; CI: confidence interval.
the third author (Yeung) was consulted. Relevant reports’ information on the author, year, number of participants, intervention (weeks, frequency, and dosage), and passive control condition were extracted and recorded in an excel spreadsheet. The authors of the identified papers were contacted for additional information if necessary. The primary outcomes were all-cause mortality and cardiovascular (CV) events. The frequency of angina contributed to efficacy assessment and was included as a secondary outcome.

Hemorheology indices and cardiac function were also included as secondary outcomes, as abnormalities of these laboratory measurements are associated with CV events. The secondary outcomes also included the levels of fasting blood glucose, postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), C-reaction protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α).

RevMan 5.3 (Nordic Cochrane Center, Copenhagen, Denmark) and Stata version 15.0 (Stata Corp., College Station, TX, USA) were used to analyze the data. Continuous outcomes were pooled to find the weighted mean differences (WMDs) accompanied by 95% confidence intervals (CIs), when the outcomes were based on the same scale; otherwise, the standard mean differences (SMDs) were used. Categorical outcomes were pooled to find relative risks (RRs) and were accompanied by 95% CIs. $I^2$ statistics were used to measure heterogeneity. A fixed-effect model was used if $I^2 < 50$%; otherwise, the random-effect model was used. Publication bias was explored through a funnel-plot analysis.
2.5. Trial Sequential Analysis. In this systematic review and meta-analysis, the curative effect was exaggerated because of random errors, especially when the number of included trials or the total sample size was too small. Thus, the Trial Sequential Analysis (TSA) software version 0.9 Beta (Copenhagen Trial Unit, Copenhagen, Denmark) was used to conduct TSA analysis on the primary outcomes that could be combined and to estimate the meta-analysis sample size and the value strength of the outcome effect. In this study, an overall 5% risk of a type I error was maintained with a power of 80% [20]; the predicted risk reduction was set as 20%, and the relative event rate of the control group was derived from the meta-analysis data.

3. Results

3.1. Characteristics of the Included Trials. A total of 21 RCTs [21–41] were included in this systematic review. The study by Zhang [34] showed that the HDL levels decreased after the Xuezhikang treatment, which was contrary to the description of elevated HDL levels. Therefore, this study was excluded from our analysis. Therefore, 20 RCTs were included. One was in English, and the others were in Chinese. The publication years of these studies ranged from 2007 to 2021. The main characteristics of the individual trials are summarized in Table 1. A total of 3565 patients were included; the number of participants in each study ranged from 100 to 591 patients. Only one trial [23] did not indicate the exact number of female and male patients. The overall male to female ratio was approximately 4:3. The study period ranged from 8 weeks to 4 years. In all 20 studies, the diagnostic criteria for both DM and CHD were specified. Three studies focused on patients with stable angina pectoris, unstable angina, or acute coronary syndrome. Chinese medicines used in these studies included both herbal medicines and Chinese patent medicines. The intervention measures in the control group mainly included conventional Western medicines in line with clinical practice and lifestyle modifications, such as exercise and dietary control. Only one study reported that the placebo was delivered to participants in the control group. All 20 studies evaluated multiple outcomes at the end of treatment. Three, two, and the remaining 15 studies reported cardiovascular events, all-cause mortality, and at least two secondary outcome measures, respectively. The specific composition of TCM in the studies is listed in Table 2. Moreover, 12 trials reported adverse events.

3.2. Methodological Quality. All 20 trials claimed that the groups were randomized; nine trials [22–24, 26–28, 30, 32, 35] clearly stated the aforementioned using a random number table, while the others did not specify the method used for random sequence generation. No trials described allocation concealment. Only one trial explicitly mentioned blinding the participants and personnel [36]. The binding of outcome assessment was not specified in any of the trials. Five studies reported cases of loss to follow-up [23, 28, 33,
Overall, the methodological quality of the included trials was low according to the Cochrane Risk of Bias Tool (Figure 2).

3.3. Primary Outcomes. Three studies reported mortality and cardiovascular events. One study found no death events because of the short follow-up period. Compared to patients in the control group, the beneficial effect of TCM participation on mortality was observed (RR, 0.50; 95% CI, 0.32, 0.78; and P = 0.002) with low heterogeneity ($I^2 = 47\%$, $P = 0.17$; Figure 3).

However, the TSA result indicated a possibility of a false positive conclusion, and more trials should be included to confirm the efficacy (Figure 4). The results were more reliable when it came to reducing cardiovascular events, showing that TCM adjuvant therapy could effectively reduce the incidence of cardiovascular events (RR, 0.47; 95% CI, 0.34, 0.65; and $P < 0.001$) without heterogeneity ($I^2 = 0\%$; $P = 0.82$; Figure 5). The TSA results also supported this conclusion, as shown in Figure 6. The pooled results (Z curve, blue lines) crossed both the conventional boundary of benefit (dotted line) and the TSA boundary value curve (full line), indicating that a positive conclusion was reached even though the required information size ($n = 3102$) had not yet been reached (Figure 6).

3.4. Secondary Outcomes

3.4.1. Frequency of Angina Pectoris. Three studies reported data on the change in angina frequency with large heterogeneity. Considering that heterogeneity may be caused by different prescriptions, the pooled effect size analysis was performed according to Ning et al. [29] and Shi et al. [40], with a significant benefit of TCM (MD, -0.88; 95% CI, -1.13, -0.63; and $P < 0.001$), both of which used the Yindan Xinnao tong soft capsules (Figure 7).

3.4.2. Cardiac Function. Three studies showed an improvement of cardiac function with TCM. Compared to the control group, TCM decreased the left ventricular end-systolic
diameters (LVESD) (WMD, -4.94; 95% CI, -5.51, -4.38; P = 0.971; and I² = 0) and left ventricular end-diastolic diameter (LVEDD) (WMD, -5.06; 95% CI, -5.59, -4.54; P < 0.001; and I² = 95.9%). TCM significantly increased the left ventricular ejection fraction compared to the control group (WMD, 8.43; 95% CI, 7.89, 8.98; P < 0.001; and I² = 97.9%; Figure 8).

3.4.3. Hemorheology. Five articles reported changes in the fibrinogen (FIB) levels. The sensitivity analysis found that Ning et al. [29] reported a large effect on heterogeneity; hence, this study was removed from the analysis, and the remaining studies showed that TCM reduced the FIB levels (SMD, -0.75; 95% CI, -0.94, -0.55; P = 0.415; and I² = 0%). Six articles reported a decrease in plasma viscosity (WMD, -0.44; 95% CI, -0.46, -0.42; P < 0.001; and I² = 98%). Two articles reported that TCM had an obvious curative effect on whole blood high shear and whole blood low shear (Figure 9).

3.4.4. Systematic Inflammatory Factors. Six studies showed that TCM significantly lowered the TNF-α (WMD, -4.79; 95% CI, -5.63, -3.94; P = 0.433; and I² = 0%), IL-6 (WMD, -3.32; 95% CI, -3.88, -2.76; P < 0.001; and I² = 88.6%), and CRP (WMD, -0.43; 95% CI, -2.12, -1.04; P < 0.001; and I² = 95.3%; Figure 10) levels. These studies showed that TCM adjuvant therapy improved the HDL-C levels more effectively (WMD, 0.18; 95% CI, 0.15, 0.21; P < 0.001; and I² = 98.1%). Thirteen studies showed the advantages of TCM adjuvant therapy in reducing TC levels (WMD, -0.83; 95% CI, -0.89, -0.76; P < 0.001; and I² = 95%). Thirteen studies showed that combined TCM treatment may benefit TG reduction more (WMD, -0.55; 95% CI, -0.6, -0.5; P < 0.001; and I² = 89.7%). Moreover, 14 studies showed that combined TCM treatment could reduce LDL-C levels more effectively than conventional treatment (WMD, -0.66; 95% CI, -0.7, -0.62; P < 0.001; and I² = 95.3%; Figure 11). The subgroup analysis of follow-up and prescription is presented in Table 3.

3.4.6. Blood Glucose Levels. There were nine studies that reported a change in the HbA1c levels, showing statistically significant differences between the conventional and adjuvant TCM treatments (WMD, -1.29; 95% CI, -1.38, -1.2; P < 0.001; and I² = 96.7%). Eleven studies showed that adjuvant TCM treatment had advantages in controlling FBC (WMD, -0.49; 95% CI, -0.59, -0.4; P < 0.001; and I² = 80.8%). Further, 11 studies found that TCM intervention reduced the PBG levels more effectively (WMD, -0.98; 95% CI, -1.1, -0.85; P < 0.001; and I² = 96.4%; Figure 12). The subgroup analysis of follow-up and prescription is presented in Table 3.

3.5. Adverse Events. Among the 12 studies that mentioned adverse events, four declared that no significant adverse

| Study     | Intervention                        | Experiment Mean±SD | Control Mean±SD | MD (95% CI) | %Weight |
|-----------|-------------------------------------|--------------------|-----------------|-------------|---------|
|           |                                     | No of subject      | No of subject   |             |         |
| Cheng 2019 | Modified yuyetang                    | 17.19±5.79         | 22.8±4.48       | -5.63      | 10.01   |
| Tao 2017  | Hedan Tablets                        | 12.42±5.85         | 17.66±5.43      | -5.28      | 19.19   |
| Zhang 2020| Xuezhikang                           | 7.96±1.76          | 10.22±2.01      | -2.66      | 11.81   |
| Statutory (I² = 88.6%, p < 0.001) |                      |                    |                 | -4.458     | 100     |

**Figure 10:** Forest plot of inflammatory factors.
events occurred with TCM. Gastrointestinal symptoms were reported in the remaining studies; Zhang et al. reported three cases of hypoglycemia, six cases of anorexia, and two cases of headache [41]. Zhao et al. reported two cases of edema, one case of mental-neurological symptoms in the experimental group, and one case of erectile dysfunction in the placebo group [36]. Other adverse events included fever [31], mild headache [25], edema, and itchy skin [21, 30, 31]. There was no statistically significant difference in the incidence of adverse events between the experimental and control groups.

3.6. Publication Bias. Funnel plots were drawn in cases where there were >10 articles to examine publication bias regarding the secondary outcomes. Because of the large heterogeneity of the studies, which was difficult to judge by funnel plots alone, Egger’s test was performed.

More than 10 studies reported information concerning the TC, TG, LDL, HDL, and 2hPG levels, of which all showed P values > 0.05 by Egger’s test, indicating no publication bias in the included studies. The funnel plot and Egger’s test results for TC, TG, LDL, HDL, and 2hPG are presented in Supplementary materials (available here).

4. Discussion. Diabetes combined with CHD increases the incidence of and mortality due to CV events. This review revealed that the use of TCM in addition to conventional treatment showed potential benefit in the treatment of DM with multiple types of CHD. Compared to the existing integrated management of glucose and cardiovascular risk factors, the addition of many TCM prescriptions formed by the delicate compatibility of herbal ingredients showed better efficacy in reducing cardiovascular events. The Standards of Medical Care for Type 2 Diabetes in China 2019 included a dedicated section focusing on TCM treatment [42].
| Outcomes | No. of studies | No. of experiment | No. of control | MD   | 95% CI            | P value  | I² (%) |
|---------|----------------|------------------|----------------|------|------------------|----------|--------|
| TC      |                |                  |                | -1.03 | -1.46, -0.60    | <0.001   | 95.2   |
|         | **Subgroup: follow-up** |          |                |       |                  |          |        |
| 2 months| 3              | 168             | 160            | -1.41 | -2.67, -0.15     | <0.001   | 96.1   |
| 3 months| 8              | 541             | 526            | -1.02 | -1.61, -0.42     | <0.001   | 95.1   |
| 6 months| 1              | 75              | 75             | -0.83 | -1.16, -0.49     |          |        |
| 4 years | 1              | 285             | 306            | -0.29 | -0.45, -0.13     |          |        |
|         | **Subgroup: prescription** |        |                |       |                  |          |        |
| Xuezhikang | 2            | 373             | 352            | -0.63 | -1.34, 0.07      | <0.001   | 92.1   |
| TG      |                |                  |                | -0.93 | -1.32, -0.53     | <0.001   | 94.3   |
|         | **Subgroup: follow-up** |          |                |       |                  |          |        |
| 2 months| 3              | 168             | 160            | -1.02 | -2.06, -0.03     | <0.001   | 94.8   |
| 3 months| 8              | 541             | 526            | -1.03 | -1.54, -0.53     | <0.001   | 93.3   |
| 6 months| 1              | 75              | 75             | -0.697| -1.026, -0.367   |          |        |
| 4 years | 1              | 285             | 306            | -0.062| -0.223, 0.099    |          |        |
|         | **Subgroup: prescription** |        |                |       |                  |          |        |
| Xuezhikang | 2            | 373             | 352            | -0.46 | -1.27, 0.35      | <0.001   | 94.2   |
| HDL     |                |                  |                | 0.72  | 0.41, 1.02       | <0.001   | 90.7   |
|         | **Subgroup: follow-up** |          |                |       |                  |          |        |
| 2 months| 1              | 68              | 60             | 1.39  | 1.01, 1.78       |          |        |
| 3 months| 8              | 619             | 604            | 0.8   | 0.54, 1.06       | <0.001   | 79.5   |
| 6 months| 1              | 75              | 75             | 0.096 | -0.224, 0.417    |          |        |
| 4 years | 1              | 306             | 285            | 0.141 | -0.02, 0.3       |          |        |
|         | **Subgroup: prescription** |        |                |       |                  |          |        |
| Xuezhikang | 2            | 373             | 352            | 0.29  | -0.06, 0.63      | 0.066    | 70.5   |
| LDL     |                |                  |                | 0.5   | -1.20, -0.79     | <0.001   | 95.2   |
|         | **Subgroup: follow-up** |          |                |       |                  |          |        |
| 2 months| 2              | 110             | 118            | -0.88 | -1.15, -0.6      | 0.711    | 0      |
| 3 months| 10             | 744             | 729            | -1.38 | -1.95, -0.81     | <0.001   | 95.8   |
| 6 months| 1              | 75              | 75             | -0.898| -1.23, -0.56     |          |        |
| 4 years | 1              | 306             | 285            | -0.459| -0.62, -0.3      |          |        |
|         | **Subgroup: prescription** |        |                |       |                  |          |        |
| Xuezhikang | 2            | 373             | 352            | -0.49 | -0.64, -0.34     | 0.337    | 0      |
| FBG     |                |                  |                | -0.5  | -0.67, -0.33     | <0.001   | 72.4   |
|         | **Subgroup: follow-up** |          |                |       |                  |          |        |
| 2 months| 4              | 358             | 275            | -0.44 | -0.73, -0.15     | 0.04     | 64.9   |
| 3 months| 8              | 725             | 710            | -0.49 | -0.7, -0.27      | <0.001   | 76.5   |
| 6 months| 1              | 60              | 60             | -0.886| -1.26, -0.51     |          |        |
|         | **Subgroup: prescription** |        |                |       |                  |          |        |
| Tongxinluo | 2           | 303             | 303            | -0.43 | -0.86, -0.01     | 0.009    | 85.2   |
| HbA1c   |                |                  |                | 0.159 | -1.85, -0.47     | <0.001   | 96.9   |
The use of TSA analysis in this paper overcomes the shortcomings of a traditional systematic review or meta-analysis by avoiding hasty conclusions and ignoring the accumulation of random errors. However, it also has certain limitations: it cannot compensate for the defects in the methodological quality of the trial or the errors caused by outcome reporting bias [43].

**Figure 12: Forest plot of blood glucose levels.**
Articles have compared the efficacy of TCM in the treatment of diabetes and CHD [14], but the outcomes were clinical effectiveness rates, which varied greatly in different studies with no unified standard.

However, combined with the results of previous studies, the use of TCM for the treatment of patients with DM and CHD should be explored further to promote its application. TCM is characterized by multitargeted effects. The study herein showed beneficial ameliorative effects in the risk factors (blood glucose, lipid, cardiac function, hemorheology, and inflammatory factors) of DM combined with CHD. At present, many Chinese medicines are used to treat cases of DM combined with CHD, but the related clinical studies are insufficient, and the underlying mechanism requires further research. High-quality, randomized, double-blind clinical trials are needed to understand the associated mechanisms.

4.1. Limitations. Most of the clinical trials included in this study were high-risk trials. Although all trials claimed to use randomization, only nine described specific randomization methods. Improper randomization often leads to selection bias. At the same time, only one out of 20 studies used a double-blind design, indicating the possibility of potential errors. As the allocation is not concealed, the effect of the intervention may be exaggerated by 30–40% [44]. The reason may be that it is difficult to make a convincing placebo of TCM. This is also a prominent defect of most clinical trials of TCM.

Sensitivity analysis revealed that three studies [25, 29, 36] had a large effect on the heterogeneity of different outcome measures. The work by Zhao et al. [36] was a randomized double-blind trial with intervention for 4 years, which was much longer than the corresponding period in other clinical trials. Interestingly, they reported a clear efficacy on regulating blood lipid indicators [45]. The study suggested that long-term TCM administration may modulate blood lipids better than conventional treatment. The patients included in the study by Li et al. [25] were aged 65–85 (mean age, 74.54) years, which was higher than the corresponding mean ages in other trials. The poor glycemic control, which was possibly attributed to islet cell function, was gradually lost in elderly patients with DM. The patients in the study by Ning et al. [29] received nitrate ester, which can improve hemodynamics and can explain the better control in FIB than other study.

The main sources of heterogeneity were the following: (1) Study protocol designs were not rigorous. (2) The interventions differed greatly in composition, dosage, dosage form, and intervention time. In the theory of TCM, individuals adapted in different formulas for treating DM and CHD are different. Meanwhile, the different dosage forms of TCMs also indicate problems in the quality control of TCMs. (3) Basal interventions differed.

Considering the complicated sources of heterogeneity, we found it difficult to reduce the high heterogeneity through subgroup analysis.

On the one hand, different TCM interventions are main sources of heterogeneity. On the other hand, there are differences in the type of heterogeneity. In addition, although patient baselines were comparable in independent studies, patient conditions, including the severity of CHD, varied between studies.

5. Conclusions

Through this systematic review and meta-analysis of adjuvant TCM treatment of CHD in patients with DM, we found that TCM could improve the control effect of conventional treatment on blood glucose, blood lipid, and inflammation, thereby reducing the frequency of angina and the incidence of cardiovascular events and all-cause mortality; this indicates that TCM may be used as a complementary approach to the tertiary prevention of DM. Nevertheless, more rigorously designed RCTs and long-term evaluations are needed to support these findings. The relationship between cardiovascular benefits and TCM control of inflammation, cardiac function, and hemodynamics should be further examined.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Authors’ Contributions

Yu Wei and Qiyou Ding, the first two authors, made equal contribution to the work.

Acknowledgments

This work was partially supported by the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (grant number: ZYYCXTD-D-202001), the Young Elite Scientists Sponsorship Program by CAST (grant numbers: YESS20170034 and 2018QNR2-C10), the National Natural Science Foundation of China (grant numbers: 81904187, 81274000, and 81803923), the Special Scientific Research for Traditional Chinese Medicine of China (grant number: 201507001-11), and the Outstanding Young Scientific and Technological Talents Program (grant number: ZZ13-YQ-026). We thank the Free Statistics team for providing valuable tools for data visualization.

Supplementary Materials

Supplementary Materials The metaregression analysis of sample, publication year, and sensitivity analysis are available in supplementary materials. (Supplementary Materials)

References

[1] P. Saeedi, I. Petersohn, P. Salpea et al., “Global and regional diabetes prevalence estimates for 2019 and projections for
2030 and 2045: results from the International Diabetes Federation Diabetes Atlas," *Diabetes Research and Clinical Practice*, vol. 157, p. 107843, 2019.

[2] “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” *Journal of the American Medical Association*, vol. 285, no. 19, pp. 2486–2497, 2001.

[3] M. Laakso, “Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention," *Journal of Internal Medicine*, vol. 249, no. 3, pp. 225–235, 2001.

[4] S. Rao Kondapally Seshasai, S. Kaptoge, A. Thompson, E. Di Angelantonio, and Emerging Risk Factors Collaboration, “Diabetes mellitus, fasting glucose, and risk of cause-specific death,” *The New England Journal of Medicine*, vol. 364, no. 9, pp. 829–841, 2011.

[5] N. Li, Y. G. Yang, and M. H. Chen, “Comparing the adverse clinical outcomes in patients with non-insulin treated type 2 diabetes mellitus and patients without type 2 diabetes mellitus following percutaneous coronary intervention: a systematic review and meta-analysis,” *BMC Cardiovascular Disorders*, vol. 16, no. 1, p. 238, 2016.

[6] J. Tian, Q. Jin, Q. D. Bao et al., “Evidence and potential mechanisms of traditional Chinese medicine for the treatment of type 2 diabetes: a systematic review and meta-analysis,” *Diabetes, Obesity & Metabolism*, vol. 21, no. 8, pp. 1801–1816, 2019.

[7] M. Quarti Machado Rosa, R. dos Santos Rosa, M. G. Correia, D. V. Araujo, L. R. Bahia, and C. M. Toscano, “Disease and economic burden of hospitalizations attributable to diabetes mellitus and its complications: a nationwide study in Brazil,” *International Journal of Environmental Research and Public Health*, vol. 15, no. 2, p. 294, 2018.

[8] “9. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2018,” *Diabetes Care*, vol. 41, Supplement 1, pp. S86–S104, 2018.

[9] J. R. Guyton, H. E. Bays, S. M. Grundy, T. A. Jacobson, and The National Lipid Association Statin Intolerance Panel, "An assessment by the Statin Intolerance Panel: 2014 update," *Journal of Clinical Lipidology*, vol. 8, no. 3, pp. S72–S81, 2014.

[10] X. L. Tong, L. Dong, L. Chen, and Z. Zhen, “Treatment of diabetes using traditional Chinese medicine: past, present and future,” *The American Journal of Chinese Medicine*, vol. 40, no. 5, pp. 877–886, 2012.

[11] X. L. Tong, S. T. Wu, F. M. Lian et al., “The safety and effectiveness of TM81, a Chinese herbal medicine, in the treatment of type 2 diabetes: a randomized double-blind placebo-controlled trial,” *Diabetes, Obesity & Metabolism*, vol. 15, no. 5, pp. 448–454, 2013.

[12] J. Xu, F. Lian, L. Zhao et al., “Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula,” *The ISME Journal*, vol. 9, no. 3, pp. 552–562, 2015.

[13] F. Lian, J. Tian, X. Chen et al., “The efficacy and safety of Chinese herbal medicine Jinlida as add-on medication in type 2 diabetes patients ineffectively managed by metformin monotherapy: a double-blind, randomized, placebo-controlled, multicenter trial,” *PLoS One*, vol. 10, no. 6, p. e0130550, 2015.

[14] K. J. Zhang, Q. Zheng, P. C. Zhu et al., “Traditional Chinese medicine for coronary heart disease: clinical evidence and possible mechanisms,” *Frontiers in Pharmacology*, vol. 10, p. 844, 2019.

[15] X. Yu, L. Xu, Q. Zhou et al., “The efficacy and safety of Chinese herbal formula, JTZZ, for the treatment of type 2 diabetes with obesity and hyperlipidemia: a multicenter randomized, positive-controlled, open-label clinical trial,” *International Journal of Endocrinology*, vol. 2018, Article ID 9519231, 11 pages, 2018.

[16] H. S. Fang, C. C. Liu, C. H. Jia, Y. H. Chen, and C. Y. Li, “Risk of developing coronary artery disease in patients with type 2 diabetes receiving traditional Chinese medicine therapy,” *Journal of Alternative and Complementary Medicine*, vol. 21, no. 10, pp. 604–609, 2015.

[17] X. Y. Guo, L. I. U. Jing, L. I. U. Jun et al., “Use of traditional Chinese medicine in Chinese patients with coronary heart disease,” *Biomedical and Environmental Sciences*, vol. 26, no. 4, pp. 303–310, 2013.

[18] M. J. Page, J. E. McKenzie, P. M. Bossuyt et al., “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews," *BMJ*, vol. 372, article n71, 2021.

[19] J. P. Higgins, D. G. Altman, P. C. Gotzsche et al., “The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials,” *BMJ*, vol. 343, no. oct 18 2, p. d5928, 2011.

[20] J. Wetterslev, K. Thorlund, J. Brok, and C. Gluud, “Estimating required information size by quantifying diversity in random-effects model meta-analyses,” *BMC Medical Research Methodology*, vol. 9, no. 1, p. 86, 2009.

[21] C. H. Qian and Q. Yu, “The therapeutic effect of tongguan huxue decoction and naxiontong capsule on diabetic patients with coronary heart disease and its effects on glycolipid, HMGBl and Omentin-1 levels," *Modern Journal of Integrated Traditional Chinese and Western Medicine*, vol. 27, no. 13, pp. 1435–1438, 2018.

[22] C. Chen, J. H. Zhang, X. Liu, D. P. Liu, P. Sun, and S. B. Liu, “Effects of Yans Yixin prescription and Levocarnitine on serum amyloid a, a matrix metalloproteinase-9 and bilirubin in patients with diabetes and angina pectoris,” *Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease*, vol. 17, no. 7, pp. 1032–1036, 2019.

[23] L. Cheng, Z. C. Li, and J. G. Liang, “Clinical efficiency of modified Yuyetang to type 2 diabetes mellitus combined with coronary heart disease," *Chinese Journal of Experimental Traditional Chinese and Western Medicine*, vol. 25, no. 21, pp. 78–83, 2019.

[24] S. Gao, X. Tian, W. N. Jiang, and Y. Ma, “Clinical efficacy of integrated traditional Chinese and Western medicine in the treatment of type 2 diabetes complicated with coronary heart disease and its effect on serum fibroblast growth factor-21 and ghrelin," *Journal of Hainan Medical University*, vol. 24, no. 12, pp. 1954–1958, 2018.

[25] C. L. Li, J. J. Sun, and W. X. Zhang, “Clinical observation of 100 cases of diabetes mellitus with myocardial ischemic coronary heart disease treated with Jiangtangshengmianyin," *Lishizhen Medicine and Materia Medica Research*, vol. 7, pp. 1685–1686, 2008.

[26] S. Y. Liu, P. H. Song, and P. N. Zhang, “Clinical observation of 130 cases of type 2 diabetes mellitus with coronary heart disease treated with Xinshu pill," *Journal of New Chinese Medicine*, vol. 1, pp. 40–42, 2008.

[27] Y. Liu, K. H. Han, and Q. Wang, “Effect of Shexiang Yangxin powder on diabetic mellitus complicated with coronary athrosclerotic heart disease and its influence on blood lipid, hemorheological index and coagulation function," *Shannxi Journal of Traditional Chinese Medicine*, vol. 40, no. 5, pp. 576–579, 2019.
[28] Q. Ni, X. F. Yan, and L. Lin, “Clinical study on the effect of Xuezhikang capsule in treating 128 patients with diabetic coronary heart disease and angina,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 17, no. 10, pp. 9–11, 2010.

[29] G. J. Ning, M. X. Li, W. D. Ren, and W. J. Deng, “Effect of Yindan Xinnaotong soft capsule on the oxidative stress and vascular endothelial function in patients with T2DM complicated with CHD,” Journal of Bengbu Medical College, vol. 42, no. 11, pp. 1472–1475, 2017.

[30] Z. M. Tao, D. P. Wang, S. Z. Zhang, and R. Kong, “Effects of Hedan tablets on the levels of blood lipid, inflammatory factors and oxidative stress in coronary heart disease patients with type 2 diabetes mellitus,” China Pharmacy, vol. 28, no. 23, pp. 3244–3247, 2017.

[31] C. Zhang and Y. C. Pan, “Effect of traditional Chinese medicine prescription on type 2 diabetes mellitus with stable angina pectoris,” Chinese Journal of Public Health Engineering, vol. 18, no. 2, pp. 306–308, 2019.

[32] D. Z. Qian, “Clinical research moods capsule intervention in diabetic patients with acute coronary syndrome,” Chinese Journal of Heart and Heart Rhythm (Electronic Edition), vol. 5, no. 2, pp. 103–105, 2017.

[33] X. Y. Zhang and J. C. Hu, “Clinical effect of Shuxin huoxue decoction on type 2 diabetes mellitus combined with coronary heart disease,” Chinese Journal of Clinical Rational Drug Use, vol. 8, no. 29, pp. 44–45, 2015.

[34] H. Y. Zhang, “Effect of Shexiang Baoxin Pill combined with trimetazidine on diabetes mellitus with coronary heart disease and its effect on hemorheology and blood lipid,” Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, vol. 15, no. 10, pp. 1231–1233, 2017.

[35] J. Zhang, Y. Liu, J. Y. Wang et al., “Yiqi Yangyin therapy in the treatment of type 2 diabetes mellitus with stable angina pectoris,” Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, vol. 17, no. 15, pp. 2249–2253, 2019.

[36] S. P. Zhao, Z. L. Lu, B. M. Du et al., “Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS),” Journal of Cardiovascular Pharmacology, vol. 49, no. 2, pp. 81–84, 2007.

[37] F. Tong, “Clinical analysis of Shexiang Baoxin Pill combined with Trimetazidine in treating diabetes complicated with coronary heart disease,” Diabetes World, vol. 17, no. 4, pp. 11–12, 2020.

[38] L. Li, “Effect of Tongxinluo capsules combined with trimetazidine in the treatment of coronary heart disease associated with diabetes mellitus,” Women’s Health Research, vol. 1, pp. 23–24, 2021.

[39] R. E. N. Yujun, B. Jianxue, Z. Mingde, and C. Yingjiang, “Effect of Tongxinluo, Jinilida combined with metoprolol in the treatment of patients with diabetes mellitus complicated with coronary heart disease and the influence on cardiac function and blood glucose indicators,” Clinical Medical & Engineering, vol. 27, no. 9, pp. 1199–1200, 2020.

[40] S. Hang, L. Liqun, and C. Jiye, “Clinical efficacy of yin Dan Xinnao soft capsule for the treatment of elderly patients with unstable angina and type 2 diabetes mellitus,” Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, vol. 18, no. 1, pp. 183–185, 2020.

[41] Z. Mao, Y. Qi-Cai, J. Rong-Lu, and S. H. E. N. Bing, “Therapeutic effect of Xuezhikang combined liraglutide and metformin on DM+CHD patients,” Chinese Journal of Cardiovascular Rehabilitation Medicine, vol. 29, no. 3, pp. 326–332, 2020.

[42] W. Jia, J. Weng, D. Zhu et al., “Standards of medical care for type 2 diabetes in China 2019,” Diabetes/Metabolism Research and Reviews, vol. 35, no. 6, p. e3158, 2019.

[43] J. Wetterslev, K. Thorlund, J. Brok, and C. Gluud, “Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis,” Journal of Clinical Epidemiology, vol. 61, no. 1, pp. 64–75, 2008.

[44] H. Yin, Y. Zhang, L. Yang, G. Bai, D. Shi, and K. Chen, “The effects of PQS on glucose transport, GLUT4 translocation and CAP mRNA expression of adipocytes,” Chinese Pharmacological Bulletin, vol. 23, no. 10, pp. 1332–1337, 2007.

[45] M. Li, Q. He, Y. Chen et al., “Xuezhikang capsule for type 2 diabetes with hyperlipemia: a systematic review and meta-analysis of randomized clinical trails,” Evidence-based Complementary and Alternative Medicine, vol. 2015, Article ID 468520, 13 pages, 2015.

[46] M. Wang, Y. Shan, W. Sun et al., “Effects of Shexiang Baoxin Pill for coronary microvascular function: a systematic review and meta-analysis,” Frontiers in Pharmacology, vol. 12, p. 751050, 2021.

[47] P. Yang, P. Liu, and R. Yang, “Systematic review of Tongxinluo capsule on the therapeutic effect and Hemorheology of patients with transient ischemic attack,” Evidence-based Complementary and Alternative Medicine, vol. 2021, 10 pages, 2021.

[48] B. Liu, C. J. Yu, X. B. Meng et al., “Effects of QiZhi JianTang capsule on dermal ulcer in type 2 diabetic rats,” Zhongguo Zhong Yao Za Zhi, vol. 41, no. 1, pp. 118–123, 2016.

[49] J. Pan, Y. Xu, S. Chen et al., “The effectiveness of traditional Chinese medicine Jinlida granules on glycemic variability in newly diagnosed type 2 diabetes: a double-blinded, randomized trial,” Journal Diabetes Research, vol. 2021, p. 6303063, 2021.